DUBLIN--(BUSINESS WIRE)--The "Transdermal Scopolamine: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027
In the changed post COVID-19 business landscape, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027.
The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR
The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.
Select Competitors (Total 41 Featured) -
- Alchem International
- Alkaloids of Australia
- ALZA Corporation
- Baxter International Inc.
- Caleb Pharmaceuticals Inc
- Centroflora-Cms
- Fine Chemicals Corporation
- GlaxoSmithKline Plc
- Myungmoon Pharma Co. Ltd.
- Novartis AG
- Perrigo Co. Plc
- Phytex Australia
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Transdermal Scopolamine - Global Key Competitors Percentage Market Share in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
Companies Mentioned
- Alchem International
- Alkaloids of Australia
- ALZA Corporation
- Baxter International Inc.
- Caleb Pharmaceuticals Inc
- Centroflora-Cms
- Fine Chemicals Corporation
- GlaxoSmithKline Plc
- Myungmoon Pharma Co. Ltd.
- Novartis AG
- Perrigo Co. Plc
- Phytex Australia
For more information about this report visit https://www.researchandmarkets.com/r/mjl3iv
